Argenx Reports Results of VYVGART Hytrulo in P-III study for Primary Immune Thrombocytopenia
Shots:
- The P-III study (ADVANCE-SC) evaluating Efficacy and the Safety of Vyvgart Hytrulo Subcutaneous vs PBO in Adult Patients (n=207) with Primary Immune Thrombocytopenia in 2:1 ratio
- The 1EP was not achieved, with 13.7% of treated patients showing sustained platelet count response vs 16.2%. Additionally, 2EP incl. additional endpoint on International Working Group responder status and mean platelet count change from Baseline, were also not met. Tolerability & safety profile was consistent with previous study data
- Vyvgart Hytrulo, a subcutaneous combo of efgartigimod alfa and rHuPH20 using Halozyme's ENHANZE, drug delivery technology to facilitate subcutaneous injection delivery of biologics for IgG reduction
Ref: Globenewswire | Image: argenx
Related News:- argenx’s Vyvgart with Halozyme’s Enhanze Receives the EC’s Approval for the Treatment of Generalized Myasthenia Gravis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
